| Literature DB >> 32170161 |
Tanzila Mukhtar1, Jeremie Breda2, Alice Grison1, Zahra Karimaddini3,4, Pascal Grobecker2, Dagmar Iber3,4, Christian Beisel5, Erik van Nimwegen2, Verdon Taylor6.
Abstract
Neural stem cells (NSCs) generate neurons of the cerebral cortex with distinct morphologies and functions. How specific neuron production, differentiation and migration are orchestrated is unclear. Hippo signaling regulates gene expression through Tead transcription factors (TFs). We show that Hippo transcriptional coactivators Yap1/Taz and the Teads have distinct functions during cortical development. Yap1/Taz promote NSC maintenance and Satb2+ neuron production at the expense of Tbr1+ neuron generation. However, Teads have moderate effects on NSC maintenance and do not affect Satb2+ neuron differentiation. Conversely, whereas Tead2 blocks Tbr1+ neuron formation, Tead1 and Tead3 promote this early fate. In addition, we found that Hippo effectors regulate neuronal migration to the cortical plate (CP) in a reciprocal fashion, that ApoE, Dab2 and Cyr61 are Tead targets, and these contribute to neuronal fate determination and migration. Our results indicate that multifaceted Hippo signaling is pivotal in different aspects of cortical development.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32170161 PMCID: PMC7070074 DOI: 10.1038/s41598-020-61490-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Transcriptional dynamics of Hippo effectors in NSCs, BPs, NBNs from RNA sequencing data. (a) Schematic representation of mouse developing cortex. NSCs reside in the VZ, with long processes extending from apical to basal surface. NSCs are labelled by Hes5::GFP. BPs express high levels of Tbr2::GFP (Tbr2::GFPbright) and NBNs express low levels of Tbr2::GFP (Tbr2::GFPdim) expression. (b) Experimental paradigm used. 3–4 RNA samples extracted from FAC-sorted GFP+ NSCs, BPs and NBN populations each day during development, from biological replicates, following the time-course (E10.5 to PN), through phases of expansion, neurogenesis and gliogenesis. cDNA libraries were prepared and Next-Generation RNA-sequencing performed. (c) Expression profiles of Hippo signaling effectors; receptors Fat1 and Crb2, ligands Dchs1, CD44, co-activators Yap1, Taz, transcription factors Tead1, Tead2, Tead3 in NSCs, BPs and NBNs show dynamics during corticogenesis in these populations. Y-axis: mRNA level expressed as log2 TPM (transcripts per million). Also see Figs. S1 and S2. NSCs- Neural stem cells, BPs- Basal progenitors, NBNs- Newborn neurons, VZ - ventricular zone, SVZ - subventricular zone, IZ - intermediate zone, CP - cortical plate, E - Embryonic day, PN - postnatal day 1.
Figure 2Overexpression of co-activators Yap1 and Taz affects cell fate, neuronal migration and cortical layering. (a) Experimental paradigm used to perform overexpression of Yap1 and Taz, and GFP as a control. IUEs were performed at E13.5 and brains isolated at and analyzed at E15.5, after 48 hours. (b) Illustration to show the sequential generation of distinct types of cortical layers, specified by different TFs. The cortical development is divided in expansion, neurogenesis and gliogenesis. (c) Coronal sections of transfected cortices immunostained for GFP and Tbr1, deep layer marker. (d) Quantification of Tbr1+GFP+ cells shows a reduction upon overexpression of Yap1 and Taz, compared to GFP control in CP and total. (e) Coronal sections of transfected cortices immunostained for GFP and Ctip2, deep layer marker. (f) Quantification of Ctip2+GFP+ cells shows a reduction compared to GFP control in CP and no change in total, upon overexpression of Yap1 and Taz. IUE- in utero electroporation. Total = VZ+SVZ/IZ+CP. Also see Fig. S3. Summaries of the quantifications are in Table S1. Scale bar = 50 μm. Data are shown as average ± SEM, *p = 0.05, **p = 0.01, ***p = 0.001.
Figure 3Overexpression of Tead1, Tead2, Tead3 affect cell fate, neuronal migration and cortical layering. (a) Experimental paradigm used to perform overexpression of Tead1, Tead2 and Tead3 and empty GFP as a control. IUE were performed at E13.5 and brains isolated at E15.5, after 48 hours. (b) Coronal sections of transfected cortices immunostained for GFP and Pax6, NSC marker. (c) Quantification of distribution of GFP+ transfected cells shows Tead1 and Tead3 induce similar phenotypic changes in cell distribution while Tead2 overexpression shows an opposite phenotype. (d) Quantification of Pax6+GFP+ cells shows an increase in total Pax6+ cells upon overexpression of Tead3, compared to GFP control in VZ and total. Also see Fig. S4. Summaries of the quantifications are in Table S2. Scale bar = 50 μm. Data are shown as average ± SEM, *p = 0.05, **p = 0.01, ***p = 0.001.
Figure 4Dominant negative forms of Tead1, Tead2 and Tead3 show reciprocal phenotypes to their corresponding overexpression. (a) Experimental paradigm used to perform loss of function of Tead1, Tead2 and Tead3 and empty GFP as a control. DN constructs were cloned without the DNA-binding domains. IUE were performed at E13.5 and brains isolated at E15.5, after 48 hours. (b) Coronal sections of transfected cortices immunostained for GFP and Pax6. (c) Quantification of distribution of GFP+ transfected cells shows Tead1 DN and Tead3 DN induce similar phenotypic changes in cell distribution while Tead2 DN shows an opposite phenotype. (d) Quantification of Pax6+GFP+ cells shows an increase in total Pax6+ upon Tead1 DN, Tead2 DN and Tead3 DN, compared to GFP control in VZ and total. DN - Dominant negative, tTead = Truncated Tead, Y/TBD = Yap1/Taz binding domain. Also see Fig. S5. Summaries of the quantifications are in Table S3. Scale bar = 50 μm. Data are shown as average ± SEM, *p = 0.05, **p = 0.01, ***p = 0.001.
Figure 5Transactive forms of Tead1 and Tead2 show similar phenotypic changes. (a) IUE with the transactive forms (with VP16 domain) of Tead1 and Tead2 were performed at E13.5 and brains isolated at E15.5, after 48 hours. (b) Coronal sections of transfected cortices immunostained for GFP and Pax6. (c) Quantification of distribution of GFP+ transfected cells shows Tead1 VP16 and Tead2 VP16 induce similar phenotypic changes in cell distribution. (d) Quantification of Pax6+GFP+ cells shows an increase in total Pax6+ cells upon Tead1 VP16, Tead2 VP16 compared to GFP control in all zones. Summaries of the quantifications are in Table S4. Scale bar = 50 μm. Data are shown as average ± SEM, *p = 0.05, ***p = 0.001, ****p = 0.0001.
Figure 6In silico predicted Tead targets by ISMARA and their experimental validation. (a) Activity of Tead binding motif in NSCs during expansion, neurogenesis and gliogenesis. (b) Examples of in silico predicted targets of Tead. (c) Chromatin Immunoprecipitation for flag tagged-Tead1 and Tead2, performed in adherent NSCs, 48 hours after nucleofection. (d) ChIP-qPCR reproducibly pulls-down ApoE, Cyr61 and Dab2 with both Tead1 and Tead2. An empty mCherry vector was used as the negative control. (e) IUE performed with co-transfection of pBluescript-Hes5::GFP plasmid, with Tead1 and Tead2 expression constructs, at E13.5. specifically expressed in NSCs in VZ and this approach allows to isolate only transfected NSCs after 48 hours. (f) Relative expression of ApoE, Cyr61 and Dab2 mRNAs show an induced expression upon overexpression of both Tead1 and Tead2. Also see Fig. S6. Summaries of the quantifications are in Table S5. Scale bar = 100 μm. Data are shown as average ± SEM, *p = 0.05, **p = 0.01, ***p = 0.001, ****p = 0.0001.
Figure 7ApoE, Cyr61 and Dab2 overexpression recapitulate Tead overexpression phenotypic changes. (a) mRNA expression profiles of ApoE, Cyr61 and Dab2 in NSCs, BPs and NBNs. (b) Expression constructs used for overexpression. (c) Quantification of distribution of GFP+ transfected cells shows ApoE overexpression recapitulates Tead2 overexpression phenotype while Dab2 overexpression recapitulates the Tead1 overexpression phenotype. (d) Coronal sections of transfected cortices immunostained for GFP and Tbr1. (e) Quantification of Tbr1+GFP+ cells shows an increase upon overexpression of Cyr61 and Dab2, compared to GFP control in CP and all zones. Also see Figs. S7 and S8. Summaries of the quantifications are in Table S6. Scale bar = 50 μm. Data are shown as average ± SEM,*p = 0.05, **p = 0.01, ***p = 0.001, ****p = 0.0001.
| Rabbit anti-Caspase 3 (1:500) | Cell Signaling Technology | Cat# ab 9664 RRID: AB_2070042 |
| Rat anti-Ctip2 (1:500) | Abcam | Cat# ab18465, RRID: AB_2064130 |
| Mouse anti-Flag (1:1000) | Sigma | Cat# F3165; RRID: AB_259529 |
| Mouse anti-Gapdh (1:1500) | Calbiochem | Cat# CB1001, RRID: AB_2107426 |
| Sheep anti-GFP (1:250) | AbD Serotec/Biorad | Cat# 4745-1051, RRID: AB_619712 |
| Rabbit anti-HA tag (1:1000) | Cell Signaling Technology | Cat# 3724, RRID: AB_1549585 |
| Rabbit anti-pHH3 (1:500) | Millipore | Cat# ab 06-570 RRID: AB_310177 |
| Rabbit anti-Ki67 (1:500) | Abcam | Cat# ab 15580 RRID: AB_443209 |
| Rabbit anti-Pax6 (1:500) | Covance | Cat# PRB-278P, RRID: AB_291612 |
| Mouse anti-Satb2 (1:200) | Abcam | Cat# ab51502, RRID: AB_882455 |
| Rabbit anti-Tbr1 (1:500) | Abcam | Cat# ab31940, RRID: AB_2200219 |
| Rabbit anti-Tbr2 (1:400) | eBioscience | Cat# ab 14-4875-82, RRID: AB_11042577 |
| Mouse anti-Tead1 (1:200) | Santa Cruz | Cat# sc-376113 RRID: AB_10988229 |
| Rabbit anti-YAP (1:100) | Cell Signaling Technology | Cat# 14074 RRID: AB_2650491 |
| Donkey anti-Sheep, Alexa 488 (1:500) | Jackson ImmunoResearch Labs | Cat# 713-545-147, RRID: AB_2340745 |
| Donkey anti-Rabbit, Cy3 (1:500) | Jackson ImmunoResearch Labs | Cat# 711-165-152, RRID: AB_2307443 |
| Donkey anti-Mouse, Cy3 (1:500) | Jackson ImmunoResearch Labs | Cat# 715-165-151, RRID: AB_2315777 |
| Donkey anti-Rat, Cy3 (1:500) | Jackson ImmunoResearch Labs | Cat# 712-166-153, RRID: AB_2340669 |
| Donkey anti-Mouse, HRP (1:10000) | Jackson ImmunoResearch Labs | Cat# 715-035-151, RRID: AB_2340771 |
| Donkey anti-Rabbit, HRP (1:10000) | Jackson ImmunoResearch Labs | Cat# 711-035-152, RRID: AB_10015282 |
| 16% Formaldehyde Solution (w/v), methanol-free | Sigma | 28908 |
| DNase I, RNase-free | Sigma | 04716728001 |
| DNase I Grade II | Roche | 10104159001 |
| Glycine | Sigma | 50046-1KG |
| L_Cysteine | Sigma | 168149 |
| Papain | Sigma | P3125-100MG |
| Trypsin inhibitor from Glycine max (soybean) | Sigma | T6522-5x100MG |
| L15 Medium | Invitrogen | 31415029 (31415086) |
| PBS cell culture | Dulbecco | 14080089 (14080048) |
| Transfectin | BioRad | 1703351 |
| Complete Proteinase Inhibitor Cocktail | Roche | 11697498001 |
| PMSF | Sigma | P7626 (78830) |
| SensiFast SYBR Kit | Bioline | BIO-02005 |
| Triton X-100 | Fisher | BPE151-500 |
| TRIzol | Invitrogen | VX15596018 |
| Dynabeads | Invitrogen | 10765583 |
| Glycoblue Co-precipitate | Life Technologies | D1417005 |
| Bioscript, Reverse transcriptase | Bioline | BIO-27036-4 |
| Transfectin Reagent | BioRad | 1703352 |
| Fastgreen | Sigma | F7252 |
| P3 primary cell 4D-Nucleofector X kit 24 reactions | Lonza | LZ-V4XP-3024 |
| Poly L- Lysine hydrobromide | Sigma | P9155-5MG |
| Laminin | Sigma | L2020-1MG |
| Phenol-chloroform isoamyl alcohol | Life Technologies | 15593-031 |
| B27 supplement+A26 | Gibco | 17504-044 |
| Beta-mercaptoethanol | Sigma | M6250-100ML |
| DMEM/F12 | Gibco | 31966-047 |
| DMEM (high glucose) | PAN Biotech | P04-04510 |
| FBS | PAA | A15-101 |
| Nitrocellulose membrane | Protan, GE | Z670995-1EA |
| Mouse: | Verdon Taylor (Basak | Tg(Hes5-EGFP)2Vtlr |
| Mouse: | MGI | Cat# 4399136, RRID: MGI: 4399136 |
| Mouse: C57BL/6J | Janvier Labs | RRID: IMSR_JAX: 000664 |
| Neuroblastoma cells (N2A) | ATCC | Cat# CCL-131 RRID: CVCL_0470 |
| Wt Neurospheres | Derived from C57Bl/6J embryos | N/A |
| Wt adherent neural stem cells | Derived from C57Bl/6J embryos | N/A |
| pMYs-EGFP | Diepenbruck | N/A |
| pCMV-Flag-Tead1 | This paper | N/A |
| pCMV-Flag-Tead2 | RIKEN Bioresource | Cat# RDB12171 |
| pCMV-Flag-Tead3 | This paper | N/A |
| pCMV-Flag-ApoE | This paper | N/A |
| pCMV-Flag-Cyr61 | This paper | N/A |
| pCMV-Flag-Dab2 | This paper | N/A |
| pMys-HA-Yap1-IRES-GFP | Diepenbruck | N/A |
| pMys-HA-Taz-IRES-GFP | Diepenbruck | N/A |
| pMYs-HA-Tead2FL-IRES-EGFP | RIKEN Bioresource | Cat# RDB12173 |
| pMYs-HA-Tead1-VP16-IRES-EGFP | RIKEN Bioresource | Cat# RDB12172 |
| pMYs-HA-Tead2-VP16-IRES-EGFP | RIKEN Bioresource | Cat# RDB12174 |
| pCMV-Flag-Tead1-Dominant negative | This paper | (nucleotide 579-1800) |
| pCMV-Flag-Tead2-Dominant negative | This paper | (nucleotide 420-1421) |
| pCMV-Flag-Tead3-Dominant negative | This paper | (nucleotide 441-1571) |
| pBluescript- | Basak | N/A |
| ApoE_Forward_5′-CTGACAGGATGCCTAGCCG-3′ |
| N/A |
| ApoE_Reverse_5′-CGCAGGTAATCCCAGAAGC-3′ |
| N/A |
| ApoE_Forward_5′-GAGTTCGCTATCTCGGCACC-3′ | This paper | N/A |
| ApoE_Reverse_5′-TGGAAAGCAGGACTTAGCCG-3′ | This paper | N/A |
| ApoE_Forward_5′-CGCTCTTCCCAAAGGTCTGT-3′ | This paper | N/A |
| ApoE_Reverse_5′-TGGAAAGCAGGACTTAGCCG-3′ | This paper | N/A |
| ApoE_Forward_5′-CGCTGCCAAAAATTCCAGCT-3′ | This paper | N/A |
| ApoE_Forward_5′-GTACCACTTCGCAGGGATGG-3′ | This paper | N/A |
| ApoE_Reverse_Xba1_5′-ATCTCTAGATCATTGATTCTCCTGGGCCAC-3′ | This paper | N/A |
| Beta-actin_Forward_5′-AGGTGACAGCATTGCTTCTG-3′ | This paper | N/A |
| Beta-actin_Reverse_5′-GGGAGACCAAAGCCTTCATA-3′ | This paper | N/A |
| Cyr61_Forward_Not1_5′-TTCCGCGGCCGCATGAGCTCCAGCACCTTC-3′ | This paper | N/A |
| Cyr61_Reverse_Xba1_5′-CCCTCTAGATTAGTCCCTGAACTTGTGGAT-3′ | This paper | N/A |
| Dab2_Forward_5′-CCCCTGAACGGTGATACTGAT-3′ | This paper | N/A |
| Dab2_Reverse_5′-AAGTCCTGCTTTACGCCATTC-3′ | This paper | N/A |
| Dab2_1_Forward_5'-TTGGAAGACTCGGCAGACAC-3′ | This paper | N/A |
| Dab2_1_Reverse_5′-GGCCACTCCCGGTAGAGATA-3′ | This paper | N/A |
| Dab2_2_Forward_5′-GGCGCTGGGGAAATCTTACA-3′ | This paper | N/A |
| Dab2_2_Reverse_5′-CCTTGAGTCCGACCCCAAAG-3′ | This paper | N/A |
| Dab2_Forward_Not1_5′-TCGGCGGCCGCATGTCTAACGAAGTAGAAA-3′ | This paper | N/A |
| Dab2_Reverse_Xba1_5'-CCATCTAGACTAGGCAAAAGGATTTCCGAA-3′ | This paper | N/A |
| Gapdh_Forward_5′-CTCCCACTCTTCCACCTTCG-3′ | This paper | N/A |
| Gapdh_Forward_5′-CCACCACCCTGTTGCTGTAG-3′ | This paper | N/A |
| Tead1_Forward_5′-AAGCTGAAGGTAACAAGCATGG-3′ |
| N/A |
| Tead1_Reverse_5′-GCTGACGTAGGCTCAAACCC-3′ |
| N/A |
| Tead1_Forward_5′-CGCTCGCCAATGTGTGAATA-3' |
| N/A |
| Tead1_Reverse_5′-AATACACAGGCCATGCAGAG-3′ |
| N/A |
| Tead1_Forward_5′-TTCGAGAAATTCAAGCCGCC-3′ |
| N/A |
| Tead1_Reverse_5′-GAGACGATCTGGGCTGATGA-3' |
| N/A |
| Tead1_Forward_5′-CCCTCAAAACGCCTTCTTCC-3′ |
| N/A |
| Tead1_Reverse_5′-AACCTCGCATACTCCGTCTC-3′ |
| N/A |
| Tead1_Forward_5′-GACATGCTTGGTTGAACTATCCT-3′ |
| N/A |
| Tead1_Reverse-5′-GAGGGGTGATGTCTTCCTCC-3′ |
| N/A |
| Tead2_Forward_5′-CCCTCCTTGCTCTTCTGGAA-3′ |
| N/A |
| Tead2_Reverse_5′-CCACTTCACCCTACCCCAAG-3′ |
| N/A |
| Tead2_Forward_5′-CCTGTCAGATGAGGGCAAGA-3′ |
| N/A |
| Tead2_Reverse_5′-ACTTGGTCCTTCAGCTTGGA-3′ |
| N/A |
| Tead2_Forward_5′-TCCACATCAGTCAGCAGTGT-3′ |
| N/A |
| Tead2_Reverse_5′-ACTTGACGAGGAAGAAGGCA-3′ |
| N/A |
| pCMV_Tead2_Forward_HindIII_5′-ACCCAAGCTTCCACCATGGAC-3′ | This paper | N/A |
| pCMV_Tead2_Reverse_XbaI_5′-CGAGCATGCATCTAGAGGG-3′ | This paper | N/A |
| pCMV_Tead2_Reverse_5′-ATCGTCTGGAAGGCCTTGTCCTTGGAGACTTGGTCC-3′ | This paper | N/A |
| Tead2_DN_EcoRI_Forward_5′-TTCAGAATTCATGATTGCCCGTTACATCAA-3′ | This paper | N/A |
| Tead2_DN__XbaI_Reverse_5′-CCTGTCTAGACCTGAGTGTCCCTGTTTGT-3′ | This paper | N/A |
| Tead2_DN_EcoRI_Forward_ 5′-TTCAGAATTCATGTCGAGAGAAATTCAGTCCAAG-3′ | This paper | N/A |
| Tead1_DN_Not1_Forward_5'-TATTCACGCGGCCGCATGGAGCAGAGT-3′ | This paper | N/A |
| Tead1_DN_Xba1_Reverse_5′-GCCGATTCTAGATGTAGATATGGTGCTGTG-3′ | This paper | N/A |
| Tead1_Forward_5′-ACAAGGCCTTCCAGACGATG-3′ |
| N/A |
| Tead1_Reverse_5′-TGTGAGAAGGGCTTCACGTC-3′ |
| N/A |
| Tead1_transgene_Forward_5′-AAGCGGAGAATTCCACCAGG-3′ | This paper | N/A |
| Tead1_transgene_Reverse_5′-TCCTCACAAGACGTCAAGCC-3′ | This paper | N/A |
| Tead2_transgene_Forward_5′-GCCTCTGACCTACCAGGGTA-3′ | This paper | N/A |
| Tead2_transgene_Reverse_5′-TGCCTCTGGAACGAGTCAAC-3′ | This paper | N/A |
| Tead3_Not1_Forward_5′-GATCGAGCGGCCGCCACTGTGCTGGAT-3′ | This paper | N/A |
| Tead3_Xba1_Reverse-5′-TACATTTCTAGAGAGCTCGGATCCACT-3′ | This paper | N/A |
| Tead3_DN_Not1_Forward_5′-TATCGAGCGGCCGCATGGCATCCATGTCG-3′ | This paper | N/A |
| Yap1_Forward_5′-GCATGAGCAGCTACAGCATC-3′ |
| |
| Yap1_Reverse_5′-CCAAGATTTCGGAACTCAGC-3′ |
| |
| Yap1_Foward_5′-GGAGACACCATCAGCCAAAG-3′ |
| |
| Yap1_Reverse_5′-ACTCCACGTCCAAGATTTCG-3′ |
| |
| Fiji | Hosted by University of Wisconsin |
|
| Photoshop | Adobe | N/A |
| Illustrator | Adobe | N/A |
| Prism 7 | GraphPad Software, Inc |
|
| R | R Core Team |
|
| Allen Brain Atlas |
| |
| Allen Brain Atlas |
| |
| Allen Brain Atlas |
|